Journal of Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 20, 2025
As
interest
in
using
psilocybin
therapy
for
treating
mental
health
disorders
intensifies,
the
need
efficient
production
methods
becomes
increasingly
important.
Current
medical-grade
is
inefficient
and
relies
on
a
complicated
multistep
synthesis.
This
study
has
explored
evaluated
psilocin
ester
prodrugs
salts
as
potential
alternatives
to
psilocybin,
focusing
their
ease
of
synthesis,
chemical
stability,
metabolic
profiles.
A
diverse
library
15
six
was
synthesized
evaluated.
The
successfully
identified
several
that
exhibited
desirable
characteristics,
including
storage
handling
rapid
conversion
psilocin,
easy
with
advantages
over
psilocybin.
research
introduces
viable
options
through
compounds
salts,
offering
promising
avenues
future
development.
Frontiers in Pain Research,
Год журнала:
2024,
Номер
5
Опубликована: Апрель 19, 2024
Despite
research
advances
and
urgent
calls
by
national
global
health
organizations,
clinical
outcomes
for
millions
of
people
suffering
with
chronic
pain
remain
poor.
We
suggest
bringing
the
lens
complexity
science
to
this
problem,
conceptualizing
as
an
emergent
property
a
complex
biopsychosocial
system.
frame
pain-related
physiology,
neuroscience,
developmental
psychology,
learning,
epigenetics
components
mini-systems
that
interact
together
changing
socioenvironmental
conditions,
overarching
system
gives
rise
phenomenon
pain.
postulate
behavior
systems
may
help
explain
persistence
despite
current
treatments.
From
perspective,
benefit
from
therapies
can
be
both
disruptive
adaptive
at
higher
orders
within
explore
psychedelic-assisted
how
these
overlap
complement
mindfulness-based
approaches
end.
Both
mindfulness
psychedelic
have
been
shown
transdiagnostic
value,
due
in
part
effects
on
rigid
cognitive,
emotional,
behavioral
patterns
well
their
ability
promote
neuroplasticity.
Psychedelic
hold
unique
promise
management
Cancers,
Год журнала:
2024,
Номер
16(9), С. 1702 - 1702
Опубликована: Апрель 27, 2024
Despite
the
legalization
of
psilocybin
therapy
for
depression
in
terminal
illnesses
such
as
advanced
cancer
through
Oregon’s
Measure
109
2020,
significant
challenges
have
impeded
its
implementation.
This
review
synthesizes
empirical
data
supporting
utilization
addressing
cancer-related
depression,
including
an
evaluation
purported
benefits
and
potential
adverse
effects.
It
provides
a
comprehensive
examination
therapeutic
strategies,
dosing
regimens,
barriers
to
ensuring
responsible
equitable
access.
Salient
issues
explored
include
development
ethical
protocols,
integration
within
healthcare
systems,
statewide
availability,
resolving
legal
ambiguities,
defining
clinical
standards.
pioneering
role
serves
case
study,
highlighting
necessity
regulatory,
logistical,
obstacles
ensure
establishment
rigorous
care
models.
To
evaluate
the
current
level
of
evidence
for
use
psychedelics
management
cancer
pain
and
associated
psychological
distress.
Pain
is
a
common
symptom
treatment.
However,
there
are
high
rates
undertreatment
due
to
complex
underlying
biology
condition,
potentially
decrease
in
opioid
prescribing
response
epidemic.
A
diagnosis
cancer-related
can
trigger
levels
distress
throughout
Cancer
also
be
exacerbated
by
anxiety,
depression,
quality
life
challenges,
fear
death
dying,
as
well
recurrence
or
progression.
Several
pharmacologic
non-pharmacologic
approaches
have
been
utilized
mitigate
burden
with
some
success.
remains
an
unmet
need
better
symptoms.
Psychedelics,
such
lysergic
acid
diethylamide
(LSD),
psilocybin,
mescaline,
N,N-dimethyltryptamine
(DMT),
under
consideration
new
strategies
mitigating
burden.
Although
published
studies
limited,
regulatory
hurdles
decreased.
Many
clinical
trials
underway
assess
further
behavioral
counseling
patients
comorbidities
anxiety
depression.
These
examine
both
feasibility
efficacy
Early
results
promising,
additional
research
needed
understand
tolerability
broader
populations.
There
improve
Further
required
treatment
Recent
changes
paved
way
increased
on
cancer.
Journal of Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 20, 2025
As
interest
in
using
psilocybin
therapy
for
treating
mental
health
disorders
intensifies,
the
need
efficient
production
methods
becomes
increasingly
important.
Current
medical-grade
is
inefficient
and
relies
on
a
complicated
multistep
synthesis.
This
study
has
explored
evaluated
psilocin
ester
prodrugs
salts
as
potential
alternatives
to
psilocybin,
focusing
their
ease
of
synthesis,
chemical
stability,
metabolic
profiles.
A
diverse
library
15
six
was
synthesized
evaluated.
The
successfully
identified
several
that
exhibited
desirable
characteristics,
including
storage
handling
rapid
conversion
psilocin,
easy
with
advantages
over
psilocybin.
research
introduces
viable
options
through
compounds
salts,
offering
promising
avenues
future
development.
